Roche prepares for business after boom from COVID-related products
By Louis Goss
Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will stop having a "material impact" on its business after the first quarter of 2024 following the end of a boom during the pandemic.
The Basel-headquartered company posted a 6% drop in sales, to 14.4 billion Swiss francs ($15.8 billion), as an increase in the value of the Swiss franc offset a slight increase in first-quarter group-wide sales, that continued to be dragged down by lower sales of COVID-19 products.
Roche Chief Executive Thomas Schinecker, however, said that "the COVID-19-related impact on sales is largely behind us" as he forecast a return to growth this year driven by growing demand for a raft of newly launched medicines.
Shares in Roche (CH:ROG) fell 3% on Wednesday, having lost 19% of their value over the previous 12 months following a series of underwhelming results caused by a slowdown in sales of COVID-19 products.
In the first quarter, sales from Roche's pharma and diagnostics segments increased by just 2% each, at constant exchange rates, to 10.9 billion Swiss francs and 35 billion Swiss Francs respectively.
Those sales were, however, pulled down significantly by slower sales of diagnostics tests for COVID-19 and of its medicines Actemra and Ronapreve, which it gained a license to manufacture and sell outside of the U.S. after the drug was first developed by Regeneron.
Sales of Roche's COVID-19 tests fell significantly, from 300 million Swiss francs in the first quarter of 2023 to 100 million Swiss francs in the first quarter of 2024.
Roche's pharma division would have otherwise seen its sales grow by 7%, at constant exchange rates, while the company's diagnostics division would have seen its revenue increase by 8% if lower sales of COVID-19 products had been excluded.
The Swiss company, meanwhile, confirmed its outlook for 2024, signaling it will achieve "mid single digit" sales growth throughout the year, as it said lower COVID-19-related sales would stop hitting its revenue.
-Louis Goss
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-24-24 0651ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now